Journal of Medical Science & Technology
|
|
- Jared Brown
- 5 years ago
- Views:
Transcription
1 Original Article Journal of Medical Science & Technology Open Access Compare the Efficacy of Escitalopram and Amitriptyline to reduce the Suicidal Risk in Depression patients Baswaraj Munge 1, Bhavitha Gurram 2, Mundllamudi Prasad Naidu 3, Bandopadhyay Mamata 4 1 Assistant Professor, Department of Pharmacology, Maharajah s Institute of Medical Sciences (MIMS), Vizianagaram, Andhra Pradesh, India. 2 Post Graduate, Obstetrics and Gynecology, GSL Medical College, Rajhamundry, Andhra Pradesh, India. 3 PhD Scholar, Narayana Medical College and Hospital, Nellore, Andhra Pradesh, India. 4 Professor and HOD in Pharmacology Department Maharajah s Institute of Medical Sciences (MIMS),Vizianagaram, Andhra Pradesh,India. Abstract Depression is the one of the leading cause of disability for both males and females, the burden of depression is 50% higher for females than males. To evaluate and compare the efficacy of Escitalopram (SSRI) and Amitriptyline (TCA) in reducing suicidal risk in patients with depression. Patients attending the OPD of Psychiatry department of MIMS were screened for selection criteria after obtaining written informed consent. After fulfilling the selection criteria, patients were randomized into two groups. Group 1 were kept on tablet Amitriptyline 50mg /BD for 6 weeks and Group 2 were on tablet Escitalopram 10 mg/bd for 6 weeks. Total 60 patients who were newly diagnosed with moderate severe depression after fulfilling the selection criteria were included in our study. The study duration for each patient entering the study was 6 weeks. The results shows HAM-D, Pre & post treatment for Group 1 (Amitriptyline group) was significant (<0.001)*. P value of BSIS, Pre & Post treatment for Group 1 (Amitriptyline group) was significant (<0.001). (P< 0.05 is considered as significant). p value of HAM-D before & after treatment for Group 2 (Escitalopram group) was significant (<0.001)*. P value of BSIS before & after treatment for Group 2 (Escitalopram group) was significant (<0.001). Decreased suicidal risk, after treatment of Amitriptyline & Escitalopram (P value signi ficant for both treatment groups). Suicidal behavior correlates with inadequate prescription of antidepressants. In the most antidepressant prescriptions are for female patients and most suicides are committed by male individuals. Key words: Suicidal Risk, Depression, Escitalopram, Amitriptyline, HAM-D (Hamilton Depression Scale), BSIS (Beck s Suicidal Intense Scale). *Corresponding Author: Dr Baswaraj Munge, Assistant Professor, Department of Pharmacology, Maharajah s Institute of Medical Sciences (MIMS), Vizianagaram, Andhra Pradesh, India. Mobile No: mungembbs@gmail.com Received: October 21, 2014 Accepted: November 20, Published: January 20, This is an openaccess article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Introduction Depression is a state of low mood and aversion to activity that can affect a person's thoughts, behavior, feelings and physical well being.[1] Depression is the one of the leading cause of disability for both males and females, the burden of depression is 50% higher for females than males.[2] In fact, depression is the leading cause of disease burden for women in both high-income and low- and middle-income countries.[3] Suicide (Latin suicidium, from sui caedere, "to kill oneself") is the act of intentionally causing one s own death.[4] Suicide is often committed out of despair, the cause of which can be attributed to a mental disorder such as depression, bipolar disorder, schizophrenia, autism, spectrum disorders, alcoholism, or drug abuse. [5] Drugs used for Depression are Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressants (TCAs), and Monoamine Oxidase Inhibitors (MAOI) and Atypical antidepressants.[6] The baseline depression and suicidal risk were assessed by Hamilton Depression scale and Beck s suicidal intent Page13
2 scale respectively. After randomization Group 1 clinically assessed and examined on weekly basis and were kept on Tab. Amitriptyline 50mg twice daily advised to report to the hospital immediately on for 6 weeks and Group 2 were kept on Tab. encountering any discomfort or any kind of Escitalopram 10 mg twice daily for 6 weeks. After 6 problems. After the study period the patients from weeks duration of treatment, HAMD and BSIS were both the groups either continued with their respective assessed in both groups for data analysis and treatment regimens or were put on standard compared the efficacy of Escitalopram (SSRI) and antidepressant therapy depending on the efficacy and Amitriptyline (TCA) in reducing the suicidal risk. safety of the treatment regimens at the discretion of This study showed that Escitalopram (SSRI) and the clinician. Amitriptyline (TCA) observation of suicidal risk in depression patients. Methodology The study was conducted in MIMS (Maharagah s Institute of Medical Sciences). The study population was enrolled after fulfilling the selection criteria from OPD (Out Patient Department) of Psychiatry. The study was conducted from December 2011 to June The aim of this study is to evaluate and compare the efficacy of Escitalopram (SSRI) and Amitriptyline (TCA) in reducing suicidal risk in patients with depression. The objective of the study was to evaluate the level of depression and suicidal risk among the two study groups followed by evaluate and compare the efficacy and safety of Escitalopram (SSRI) and Amitriptyline (TCA) in the study groups. Both male & female subjects with recently diagnosed depression and between the age group of years were included. Patients with Schizophrenia, bipolar disorder, drug abuse (except nicotine abuse), severe Cardiovascular, Renal and liver diseases were excluded. Study design: Randomized, Single Blind, 6 Weeks Study to evaluate the Efficacy and Safety of Escitalopram (SSRI) in comparison with Amitriptyline (TCA) in reducing the suicidal risk in patients with moderate-severe depression. Total 60 patients who were newly diagnosed with moderate severe depression after fulfilling the selection criteria were included in our study. The study duration for each patient entering the study was 6 weeks. Patients attending the OPD of Psychiatry department of MIMS were screened for selection criteria after obtaining written informed consent. After fulfilling the selection criteria, patients were randomized into two groups. Group 1 were kept on tablet Amitriptyline 50mg /BD for 6 weeks and Group 2 were on tablet Escitalopram 10 mg/bd for 6 weeks. After 6 weeks the general condition of the patients was assed and then the HAMD and BSIS scoring were repeated for data analysis and report writing. In between these 6 weeks, patients were Treatment groups: (1) Group 1 Patients were kept on Tab. Amitriptyline 50mg twice daily. (2) Group 2 Patients were kept on Tab. Escitalopram 10mg twice daily. Patients were supplied with the drug on a weekly basis and were requested to return the unused tablets. Assessment of efficacy: HAM-D scale for assessment of depression-the Hamilton Depression Rating Scale (HAM-D) has proven useful for many years as a way of determining a patient s level of depression before, during, and after treatment. BECK S suicidal intent scale for assessment of suicidal risk- The BECK S suicidal intent scale is a 20-item scale for measuring negative attitudes about the future. Beck originally developed this scale in order to predict who would commit suicide and who would not. Efficacy evaluation: Percentage of change in score for Depression on HAM-D scale, over 6 week s duration of treatment. Percentage of change in score for Suicidal risk on BECK S hopelessness scale, 6 weeks duration of treatment. Assessment of Depression by Hamilton Depression Rating Scale (HAM-D): The Hamilton Depression Rating Scale (HAM -D) has proven useful for many years as a way of determining a patient s level of depression before, during, and after treatment. It should be administered by a clinician experienced in working with psychiatric patients. Statistical analysis: Using SPSS software version 10 statistical analyses was done. The treatment groups were compared for efficacy and safety variables using Student t test. Results The present study was conducted in the Department of Psychiatry, Maharajah s Institute of Medical Sciences (MIMS), Nellimarla, and Vizianagaram during the period of December 2011 to June 2012 for 6 months. 60 patients of ranging from 20 to 60 years age group were considered as subjects for the study. After Page14
3 fulfilling the selection criteria, patients were randomized into two groups. Group 1 patients were kept on Tab. Amitriptyline 50mg /twice daily for 6 weeks. Group 2 patients were kept on Tab. Escitalopram 10 mg /twice daily for 6 weeks. Table-1 Shows Pretreatment mean HAMD of Group 1 was 21.26±3.90 and pretreatment mean HAMD of Group 2 was 19.90±4.45. Pretreatment mean BSIS lof Group 1 was 32.06±5.13 and pretreatment mean BSIS of Group 2 was 30.26±6.49. Table 1: Baseline characteristics pre treatment. HAMD & BSIS scores of study population. Pre-tretment values Mean ± SD of Groups HAM- D score BSIS Score Group 1 (n = 30) ± 3.90 Group 2 (n = 30) ± 4.45 Group 1 (n = 30) ± 5.13 Group 2 (n = 30) ± 6.49 Figure 1: Pre- treatment means HAMD & BSIS score of Amitriptyline (TCA) & Esciatalopram (SSRI) Pretreatment mean HAMD score Pretreatment mean BSIS score Table-2 Post treatment HAMD mean of Group 1 was 12.10±4.81 and post treatment HAMD mean of Group 2 was 9.5±4.48. Post treatment BSIS mean of Group 1 was 7.60±2.41 and post treatment BSIS mean of Group 2 was 6.13±2.40.Table-3 Pretreatment HAMD mean of Amitriptyline (TCA) was 21±3.90, after treatment HAMD mean of Amitriptyline (TCA) was 12.10±4.81. Pretreatment BSIS mean of Amitriptyline (TCA) was 32.06±5.13, after treatment BSIS mean of Amitriptyline (TCA) was 7.6±2.41. HAMD-T value=13.61 & df =29. BSIS T value & df =29. p value of HAM-D, Pre & post treatment for Group 1 (Amitriptyline group) was significant (<0.001)*. P value of BSIS, Pre & Post treatment for Group 1 (Amitriptyline group) was significant (<0.001). ( P< 0.05 is considered as significant). N is the total number of cases. SD Standard Deviation; SEM Standard Error Mean. df Degrees of Freedom. T value is the value of Student t test. Table-4 Pretreatment mean HAMD of Escitalopram (SSRI) was 19.90±4.45, after treatment mean HAMD of Escitalopram (SSRI) was 9.5±4.84. Pretreatment mean BSIS of Escitalopram (SSRI) was 30.26±6.49, after treatment mean BSIS of Escitalopram (SSRI) was 6.13±2.40. HAMD-T value=11.73 & df =29. BSIS T value & df=29. p value of HAM-D before & after treatment for Group 2 (Escitalopram group) was significant (<0.001)*. P value of BSIS before & after treatment for Group 2 (Escitalopram group) was significant (<0.001). Post treatment values of Groups Table 2: Post treatment after 6 weeks therapy Mean ± SD HAM- D score Group 1 (n = 30) 12.1 ± 4.81 BSIS score Group 2 (n = 30) 9.5 ± 4.84 Group 1 (n = 30) 7.60 ± 2.41 Group 2 (n = 30) 6.13 ± 2.40 Figure 2: Post treatment HAMD & BSIS score of Amitriptyline (TCA) & Esciatalopram (SSRI) Post treatment mean HAMD score Post treatment mean BSIS score Page15
4 Table 3: Amitriptyline pre &post treatment mean scores of HAM-D&BSIS Group 1 Mean ± SD P value HAM-D Pre Rx (n=30) ± 3.90 <0.001* Group 2 Mean ± SD P value score Post Rx (n=30) ± 4.81 HAM-D Pre Rx (n=30) ± 4.45 BSIS Pre Rx (n=30) ± 5.13 Score Post Rx (n=30) 7.6 ± 2.41 <0.001* score Post Rx 9.5 ± 4.84 <0.001* (n=30) Table 4: Escitalopram pre & post treatment scores of HAM- BSIS Pre Rx (n=30) ± 6.49 Score Post Rx 6.13 ± 2.40 <0.001* D&BSIS. (n=30) pretreatment Posttreatment Figure 4: Escitalopram pre & post treatment mean scores of HAM-D&BSIS 0 Escitalopram(SSRI) mean HAMD score Escitaloram(SSRI) mean BSIS score Discussion Suicidal behavior correlates with inadequate prescription of antidepressants.[7] In the United States, most antidepressant prescriptions are for female patients and most suicides are committed by male individuals. Most suicides and serious nonfatal suicide attempts are committed by individuals with major depression that is untreated at the time of death.[8] These individuals may have a higher noncompliance rate with prescribed medication, especially antidepressants with more adverse effects, such as TCAs.[9] One possible cause of higher mortality due to suicide by individuals taking TCAs relative to SSRIs is that tricyclics are more toxic on overdose and death rates due to TCA overdose are higher relative to prescription volume compared with SSRIs and other new-generation antidepressants.[10] Given earlier concerns about the safety of SSRIs in adults with depression in terms of suicide risk and more recent concerns about the safety of SSRIs in youth with depression, our results and those of Olfson et al[11], who performed a similar but less sophisticated analysis in youth, indicate that more SSRI prescriptions are associated with fewer suicides in adults and youth. As per results obtained in our study, there was: significant decrease in Amitriptyline pretreatment mean HAMD score from 21±3.90SD to posttreatment mean HAMD score 12.10±4.81SD and decreased pretreatment mean BSIS score from 32.06±5.13SD to posttreatment mean BSIS score 7.6±2.41SD. Significant decrease in Escitalopram pretreatment mean HAMD score from 19.90±4.45SD to posttreatment mean HAMD score 9.5±4.84SD and decreased pretreatment mean BSIS score from 30.26±6.49 to posttreatment mean BSIS score6.13±9.40. Decreased suicidal risk, after treatment of Amitriptyline & Escitalopram (P va lue significant for both treatment groups). Pregelj P et al study, 338 patients were examined who had already been prescribed antidepressants.[12] Among patients with prescribed antidepressants 273 of them had been prescribed SSRIs and 65 had been prescribed other antidepressants. Suicidal behavior (suicidal ideations, threats and attempts) was observed in 30% of patients with prescribed SSRIs and in 38% of the patients who had been prescribed other antidepressants. Page16
5 However, the difference was not statistically significant (p>0.05). Our data gives, no evidence was found that the risk of suicide or non-fatal self harm in adults prescribed SSRIs was greater than in those prescribed other antidepressants. Hall WD et al conducted a Meta-analyses of RCTs suggest that SSRIs increase suicide ideation compared with placebo but the observational studies suggest that SSRIs do not increase suicide risk more than older antidepressants.[13] If SSRIs increase suicide risk in some patients, the number of additional deaths is very small because ecological studies have generally found that suicide mortality has declined (or at least not increased) as SSRI use has increased. The risk-benefit ratio associated with prescription of these antidepressants must be clearly favorable to explain the relationships observed in our study. The results yielded by this comparative study proved no increased suicidal risk for SSRIs or TCAs. Our results agree with studies of Isacsson G et al,[14] Markowitz JC.[15] In a study conducted by Robert D Gibbons et al, to evaluate the relationship between Antidepressant treatment and suicide attempts in adult patients. Suicide attempt rates overall as well as before and after initiation of antidepressant therapy were compared for patients who received selective serotonin reuptake inhibitors (SSRIs), new-generation non-serotonergic-specific (non-ssri) antidepressants (bupropion, mirtazapine, nefazodone and venlafaxine), tricyclic antidepressants, or no antidepressant. Suicide attempt rates were higher prior to treatment than after the start of treatment, with a significant relative risk for SSRIs and for non-ssris. For SSRIs, this effect was seen in all adult age groups. Their findings suggested that SSRI treatment has a protective effect in all adult age groups. Our study agreed with Robert D Gibbons et al.[16] In a study conducted by Pedersen AG, to evaluate the Escitalopram in major depressive disorder (MDD) and anxiety disorders. The study analysed for specific adverse events indicative of suicidal behaviour (fatal suicide, non-fatal self-harm or suicidal thoughts) in relation to treatment. The number of events was low, with no fatal suicides in the first 2 weeks of treatment. There was one fatal suicide during the full treatment period on placebo (incidence 0.1%; rate 0.003), and none on escitalopram. None of these figures were significantly different between escitalopram (n=2277) and placebo (n=1814) patients. There was no indication that escitalopram provokes suicidal behaviour compared to placebo in either MDD or anxiety disorders. Escitalopram was more efficacious versus placebo in lowering suicidal thoughts from weeks 1 through 8 in the treatment of patients with MDD. Our study correlated with Pedersen AG study [17]. In a study conducted by Yeravanian BI et al, compared the rates of suicidal behavior. [18] after discontinuation of treatment with antidepressants, and to determine the comparative rates of suicidal behaviour for patients maintained on tricyclic (TCA) vs. selective serotonin reuptake inhibitor (SSRI) antidepressants. They reviewed the charts for 521 patients with major depressive disorder and/or dysthymic disorder. Periods of active treatment or discontinuation with SSRIs or TCAs were determined. Rates of completed suicide, suicide attempts, and hospitalization for suicidality were analyzed. There was greater than a five-fold increase in risk for suicidal behaviour after discontinuation of antidepressant treatment (P < ). The rates of suicidal behavior during treatment with SSRIs or TCAs were similar. Suicidal behaviour in unipolar depressed patients treated with antidepressants increases substantially after medication discontinuation. This effect occurred in both patients who were maintained on SSRIs and TCAs. The findings support a possible protective effect on suicidal behaviour for both SSRIs and TCAs. The main limitation of this study was there is no control group. This comparative study the efficacy of two drugs was compared with each other. The placebo effect could not be evaluated for ethical reasons because the treatment groups also involved severe depression with high risk. Conclusion Suicidal risk is the one of the major problem in depression patients, who are not treating with antidepressants. Now a day s Selective Serotonin Reuptake Inhibitors(SSRIs)and Tricylic Antidepressants(TCAs) are using more to reduce depression and suicidal risk. In this study after taking Escitalopram (SSRI) and Amitriptyline (TCA), reduces suicidal risk in depression patients,when compared to before treatment.but in this study sample size is less and less studies were done in India,so further studies can be done in large population. Page17
6 References: 1. Salmans, Sandra. Depression: Questions You Have Answers You Need. People's Medical Society ISBN Marina Marcus, M. Taghi Yasamy, Mark van Ommeren, and Dan Chisholm, Shekhar Saxena, DEPRESSION, WHO, Ruchi Sundriyal1, Dr. Ravindra Kumar, Depression and Life Satisfaction among Married & Unmarried Women, IOSR Journal of Humanities and Social Science 2013; 16(3): Jablonska, Beata. "Self-inflicted injury among adolescents and young adults-the role of ethnicity, socioeconomic conditions and school performance." Mash, Eric, and David Wolfe. Abnormal child psychology. Cengage Learning, Papakostas, George I., et al. "Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents." Biological psychiatry 2007; 62(11): Rutz, Wolfgang, et al. "Prevention of depression and suicide by education and medication: impact on male suicidality. An update from the Gotland study." International Journal of Psychiatry in Clinical Practice 1997;1(1): Dopheide, Julie A. "Recognizing and treating depression in children and adolescents." American journal of health-system pharmacy 2006;63(3): Mintzer, Jacobo, and Alistair Burns. "Anticholinergic side-effects of drugs in elderly people." Journal of the Royal Society of Medicine 2000;93(9): Gillman, P. K. "Tricyclic antidepressant pharmacology and therapeutic drug interactions updated." British journal of pharmacology 2007;151(6): Olfson, Mark, et al. "National trends in the outpatient treatment of depression." Jama 2002;287(2): Zai, Clement C., et al. "The brain-derived neurotrophic factor gene in suicidal behaviour: a meta-analysis." The International Journal of Neuropsychopharmacology 2012;15(8): Hall, Wayne D., and Jayne Lucke. "How have the selective serotonin reuptake inhibitor antidepressants affected suicide mortality?." Australian and New Zealand Journal of Psychiatry 2006;40(11 12): Tondo, Leonardo, Göran Isacsson, and Ross J. Baldessarini. "Suicidal behaviour in bipolar disorder." CNS drugs 2003;17(7): Markowitz, J. C. "Antidepressants and suicide risk." The British Journal of Psychiatry 2001;178(5): Elkin, Irene, et al. "Initial severity and differential treatment outcome in the National Institute of Mental Health Treatment of Depression Collaborative Research Program." Journal of Consulting and Clinical Psychology 1995;63(5): Pedersen, Anders Gersel. "Escitalopram and suicidality in adult depression and anxiety." International clinical psychopharmacology 2005;20(3): Ansseau, Marc, et al. " Paradoxical shortening of REM latency on first recording night in major depressive disorder: Clinical and polysomnographic correlates." Biological psychiatry 1985;20(2): Page18
Illuminating the Black Box: Antidepressants, Youth and Suicide
Illuminating the Black Box: Antidepressants, Youth and Suicide David H. Rubin, M.D. Executive Director, MGH Psychiatry Academy Director, Postgraduate Medical Education Director, Child and Adolescent Psychiatry
More informationAntidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder
updated 2012 Antidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder Q10: Are antidepressants (Tricyclic antidepressants
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care R E B E C C A D. L E W I S, D O O O A S U M M E R C M E B R A N S O N, M O 1 5 A U G U S T 2 0 1 5 Objectives Understand the epidemiology of depression. Recognize
More informationGuidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive
More informationBest Practices in Prescribing Benzodiazepines. Michael Carlisle, DO Medical Director University Hospitals Geauga Medical Center
Best Practices in Prescribing Benzodiazepines Michael Carlisle, DO Medical Director University Hospitals Geauga Medical Center Objectives To review current practice guidelines in benzodiazepine prescribing
More informationOutline. Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly. Definitions
Outline Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly Michael E. Thase, MD Professor of Psychiatry Perelman School of Medicine University of Pennsylvania and Philadelphia
More informationReducing the Anxiety of Pediatric Anxiety Part 2: Treatment
Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,
More informationPharmacy Prior Authorization GMH/SA and Non-Title 19/21 SMI Non-Formulary and Prior Authorization Guidelines
Non-Formulary Behavioral Health Medications ADHD medications for children under The patient must have a diagnosis for which the requested medication is: o Approved based on FDA indication and limits; OR
More informationReviews/Evaluations. Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients. Pharmacotherapeutic Options
Reviews/Evaluations Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients Childhood major depressive disorder (MDD) has become recognized as a serious and common illness affecting between
More information1 1 Evidence-based pharmacotherapy of major depressive disorder. Michael J. Ostacher, Jeffrey Huffman, Roy Perlis, and Andrew A.
1 1 Evidence-based pharmacotherapy of major depressive disorder Michael J. Ostacher, Jeffrey Huffman, Roy Perlis, and Andrew A. Nierenberg Massachusetts General Hospital and Harvard University, Boston,
More informationAntidepressant-Induced Sexual Dysfunction: A comparison between Duloxetine and Escitalopram
Original Article Antidepressant-Induced Sexual Dysfunction: A comparison between Duloxetine and Escitalopram Anurag Jhanjee*, Pankaj Kumar*, Neeraj Kumar Gupta** *Department of Psychiatry, UCMS & GTB Hospital,
More informationGuilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.
1-800-PSYCH If you are obsessive-compulsive, dial 1 repeatedly If you are paranoid-delusional, dial 2 and wait, your call is being traced If you are schizophrenic, a little voice will tell you what number
More informationDepression in Pregnancy
TREATING THE MOTHER PROTECTING THE UNBORN A MOTHERISK Educational Program The content of this program reflects the expression of a consensus on emerging clinical and scientific advances as of the date
More informationPHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES
PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES Table of Contents Print TABLE OF CONTENTS Drug Page Number Anafranil... 2 Asendin... 4 Celexa... 4 Cymbalta... 6 Desyrel... 8 Effexor...10 Elavil...14
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 1 October 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 1 October 2008 EFFEXOR SR 37.5 mg prolonged-release capsule B/30 (CIP: 346 563-3) EFFEXOR SR 75 mg prolonged-release
More informationAntidepressants and Suicide Risk: A Comprehensive Overview
Antidepressants and Suicide Risk: A Comprehensive Overview The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Published
More informationDepression: Assessment and Treatment For Older Adults
Tool on Depression: Assessment and Treatment For Older Adults Based on: National Guidelines for Seniors Mental Health: the Assessment and Treatment of Depression Available on line: www.ccsmh.ca www.nicenet.ca
More informationPediatrics Grand Rounds 5 March University of Texas Health Science Center at San Antonio I-1
Diagnosis and Treatment of Depression in Children and Adolescents Steven R. Pliszka, M.D. Professor and Vice Chair Chief, Division of Child and Adolescent Psychiatry Department of Psychiatry The Disclosures
More informationPractice Guideline for the Treatment of Patients With Major Depressive Disorder: American Psychiatric Association
Practice Guideline for the Treatment of Patients With Major Depressive Disorder: American Psychiatric Association Our clinical advisor adds updated advice on electroconvulsive therapy, transcranial magnetic
More informationDiagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
More informationApplication of Psychotropic Drugs in Primary Care
Psychotropic Drugs Application of Psychotropic Drugs in Primary Care JMAJ 47(6): 253 258, 2004 Naoshi HORIKAWA Professor, Department of Psychiatry, Tokyo Women s Medical University Abstract: The incidence
More informationSuicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative
Suicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative Robert I. Simon, M.D.* Suicide risk is increased in patients with Major Depressive Disorder with Melancholic
More informationIt is the policy of health plans affiliated with Centene Corporation that Seroquel XR is medically necessary when the following criteria are met:
Clinical Policy: (Seroquel XR) Reference Number: CP.PMN.64 Effective Date: 12.01.14 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important
More informationEvidence-Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition
SPECIAL ARTICLE Psychiatry & Psychology http://dx.doi.org/10.3346/jkms.2014.29.4.468 J Korean Med Sci 2014; 29: 468-484 -Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition
More informationThe Safety and Efficacy of Ondansetron in the Treatment of Obsessive Compulsive Disorder
Duquesne University Duquesne Scholarship Collection Graduate Student Research Symposium The 4th Annual Graduate Student Research Symposium September 19, 2017 The Safety and Efficacy of Ondansetron in the
More informationReviewing the long-term use of selective serotonin reuptake inhibitors in patients with depression
CLINICAL AUDIT Reviewing the long-term use of selective serotonin reuptake inhibitors in patients with depression Valid to November 2022 bpac nz better medicin e Audit Focus This audit helps health professionals
More informationManual of Clinical Psychopharmacology
Manual of Clinical Psychopharmacology Fourth Edition Alan F. Schatzberg, M.D. Kenneth T. Norris, Jr., Professor and Chairman, Department of Psychiatry and Behavioral Sciences, Stanford University School
More informationThis initial discovery led to the creation of two classes of first generation antidepressants:
Antidepressants - TCAs, MAOIs, SSRIs & SNRIs First generation antidepressants TCAs and MAOIs The discovery of antidepressants could be described as a lucky accident. During the 1950s, while carrying out
More informationAugmentation and Combination Strategies in Antidepressants treatment of Depression
Augmentation and Combination Strategies in Antidepressants treatment of Depression Byung-Joo Ham, M.D. Department of Psychiatry Korea University College of Medicine Background The response rates reported
More informationExplain to patients and families the meaning and ramifications of FDA warnings regarding antidepressants. Appropriately monitor patients on
Antidepressants in Children and Adolescents: The Good, The Bad & The Ugly Raymond C. Love, Pharm.D., BCPP, FASHP Associate Dean and Professor, Pharmacy Practice & Science University of Maryland, School
More informationPart 2: Pain and Symptom Management Depression
Guidelines & Protocols Advisory Committee Part 2: Pain and Symptom Management Depression Effective Date: February 22, 2017 Key Recommendations Before diagnosing and treating major depressive disorder,
More informationMedication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford
Medication for Anxiety and Depression PJ Cowen Department of Psychiatry, University of Oxford Topics Medication for anxiety disorders Medication for first line depression treatment Medication for resistant
More informationMEDICATION ALGORITHM FOR ANXIETY DISORDERS
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences MEDICATION ALGORITHM FOR ANXIETY DISORDERS RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UNIVERSITY OF WASHINGTON
More informationMentoring Session: Participant Cases
Handout for the Neuroscience Education Institute (NEI) online activity: Mentoring Session: Participant Cases The Case: 55-year-old patient with depression and anxiety The Question: What to do when antidepressants
More informationAntidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database
open access Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database Carol Coupland, 1 Trevor Hill, 1 Richard Morriss,
More informationIlluminating the Black Box: Antidepressants, Youth and Suicide
Illuminating the Black Box: Antidepressants, Youth and Suicide David H. Rubin, M.D. Executive Director, MGH Psychiatry Academy Director, Child and Adolescent Psychiatry Residency Training, Massachusetts
More informationHazard ratio for coronary heart disease mortality for SMI patients versus controls (18-49 yrs) Hazard ratio for stroke
By Michael Dixon Contents Background to Bipolar Disorder and cardiac risk Mood stabilisers and cardiac risk factors Background to Depression and cardiac risk Antidepressants and cardiac risk factors Any
More informationD I A G N O S I S ADD/ADHD. Conduct Disorder. Oppositional. Oppositional Defiant Disorder. Defiant. Anxiety Disorder. Adjustment.
Dr. Crismon has no potential conflicts of interest to disclose with regard to this presentation. M. Lynn Crismon, Pharm.D., FCCP, BCPP Dean James T. Doluisio Regents Chair & Behrens Centennial Professor
More informationIstvan Bitter Department t of Psychiatry and Psychotherapy
Suicide in Schizophrenia & Affective disorders March 3, 2010 Istvan Bitter Department t of Psychiatry and Psychotherapy Map of Suicide Rates (per 100,000; most recent year available, March 2002) Adapted
More informationDepartment of Psychiatry & Behavioral Sciences. University of Texas Medical Branch
Depression in Childhood: Advances and Controversies in Treatment Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial Professor & Vice Chair Department of Psychiatry & Behavioral Sciences Director, Division
More informationEffect of 12 Weeks Aerobic Exercises Verses Antidepressant. Medication in Young Adult Males Diagnosed with Major Depressive.
Effect of 12 Weeks Aerobic Exercises Verses Antidepressant Medication in Young Adult Males Diagnosed with Major Depressive Disorder Jobby George* (corresponding author) 1 vv.mohan chandran 2 sandesh t.s
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care Rebecca D. Lewis, DO OOA Summer CME Oklahoma City, OK 6 August 2017 Objectives Understand the epidemiology of depression. Recognize factors to help choose antidepressants.
More informationSession outline. Introduction to depression Assessment of depression Management of depression Follow-up Review
Depression 1 Session outline Introduction to depression Assessment of depression Management of depression Follow-up Review 2 Activity 1: Person s story followed by group discussion Present the first person
More informationDISEASES AND DISORDERS
DISEASES AND DISORDERS 13. The mood (affective) disorders 99 14. The psychotic disorders: schizophrenia 105 15. The anxiety and somatoform disorders 111 16. Dementia and delirium 117 17. Alcohol and substance-related
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDisclosure Information
Disclosure Information I have no financial relationships to disclose. I will discuss the off label use of several depression and anxiety medications in pediatric population Pediatric Depression & Anxiety
More informationObjectives. Objectives. A practice review. 02-Nov-16 MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS
MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS Jon-Paul Khoo What is treatment resistance really? Database review 328 consecutive non-remitted MDD patients referred for private
More informationDrugs, Society and Behavior
SOCI 270 Drugs, Society and Behavior Spring 2016 Professor Kurt Reymers, Ph.D. Chapter 8 Medication for Mental Disorders 1. Mental Disorders: a. The Medical Model Model: symptoms diagnosis determination
More informationDrug Prescribing Pattern for Patients of Anxiety and Depression Attending Psychiatry OPD of a Tertiary Care Teaching Hospital in North India
Original Research Article Drug Prescribing Pattern for Patients of Anxiety and Depression Attending Psychiatry OPD of a Tertiary Care Teaching Hospital in North India Akanksha Garg, Surabhi Gupta*, Sandeep
More informationSummary of guideline for the. treatment of depression RANZCP CLINICAL PRACTICE GUIDELINES ASSESSMENT
RANZCP CLINICAL PRACTICE GUIDELINES Summary of guideline for the RANZCP CLINICAL PRACTICE GUIDELINES treatment of depression Pete M. Ellis, Ian B. Hickie and Don A. R. Smith for the RANZCP Clinical Practice
More information5 COMMON QUESTIONS WHEN TREATING DEPRESSION
5 COMMON QUESTIONS WHEN TREATING DEPRESSION Do Antidepressants Increase the Possibility of Suicide? Will I Accidentally Induce Mania if I Prescribe an SSRI? Are Depression Medications Safe and Effective
More informationSetting The setting was primary and secondary care. The economic evaluation was conducted in France.
Cost-effectiveness of mirtazapine relative to fluoxetine in the treatment of moderate and severe depression in France Brown M C, van Loon J M, Guest J F Record Status This is a critical abstract of an
More informationTaking Care: Child and Youth Mental Health TREATMENT OPTIONS
Taking Care: Child and Youth Mental Health TREATMENT OPTIONS Open Learning Agency 2004 TREATMENT OPTIONS With appropriate treatment, more than 80% of people with depression get full relief from their symptoms
More information11. Psychopharmacological Intervention
11. Psychopharmacological Intervention 11.1 Goals of Psychopharmacology The goal of psychopharmacology is to ensure that patients with more severe forms of depression and those who fail to benefit adequately
More informationAntidepressant use and risk of adverse outcomes in people aged years: cohort study using a primary care database
Coupland et al. BMC Medicine (2018) 16:36 https://doi.org/10.1186/s12916-018-1022-x RESEARCH ARTICLE Open Access Antidepressant use and risk of adverse outcomes in people aged 20 64 years: cohort study
More informationDEPRESSION AND SUICIDE PREVENTION. Michelle Giddings, DNP, APRN, FNP-BC, PMHNP-BC
DEPRESSION AND SUICIDE PREVENTION Michelle Giddings, DNP, APRN, FNP-BC, PMHNP-BC Learning Objectives Increase awareness about depression and suicide prevention. Identify risk factors of depression and
More informationGraylands Hospital Drug Bulletin
Graylands Hospital Drug Bulletin Antidepressant Combination and Augmentation Strategies North Metropolitan Area Mental Health Service October 2008 Vol 15 No.4 ISSN 1323-1251 Introduction Depression is
More informationKEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.
KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised
More informationPTSD: Treatment Opportunities
PTSD: Treatment Opportunities Professor Malcolm Hopwood Department of Psychiatry University of Melbourne Professorial Psychiatry Unit, Albert Road Clinic DSM 5: PTSD CRITERION A exposure to: actual or
More informationContemporary Psychiatric-Mental Health Nursing. Psychopharmacology. Psychopharmacology - continued. Chapter 7 The Science of Psychopharmacology
Contemporary Psychiatric-Mental Health Nursing Chapter 7 The Science of Psychopharmacology Psychopharmacology A primary treatment mode of psychiatric-mental health nursing care Psychopharmacology - continued
More informationPrepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D.
Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D. Sources: National Institute of Mental Health (NIMH), the National Alliance on Mental Illness (NAMI), and from the American Psychological Association
More informationCHAPTER 6: ANXIETY AND STRESSOR-RELATED PROBLEMS KEY TERMS
CHAPTER 6: ANXIETY AND STRESSOR-RELATED PROBLEMS KEY TERMS Affectionless Control A type of parenting characterized by high levels of overprotection combined with a lack of warmth and care. Amygdala The
More informationSuicidal Ideation & Behavior Discussion. Roger E. Meyer, MD Professor of Psychiatry Penn State Hershey Medical Center
Suicidal Ideation & Behavior Discussion Roger E. Meyer, MD Professor of Psychiatry Penn State Hershey Medical Center FDA Guidance Documents 2010 & 2012 2010 Suicidal ideation 2012 Passive Suicidal ideation
More informationPsychiatry curbside: Answers to a primary care doctor s top mental health questions
Psychiatry curbside: Answers to a primary care doctor s top mental health questions April 27, 2018 Laurel Ralston, DO Psychiatrist, Taussig Cancer Institute Objectives Review current diagnostic and prescribing
More informationA Comparative Study of Socio Demographic and Clinical Profiles in Patient with Obsessive Compulsive Disorder and Depression
American Journal of Psychiatry and Neuroscience 2018; 6(4): 99-103 http://www.sciencepublishinggroup.com/j/ajpn doi: 10.11648/j.ajpn.20180604.12 ISSN: 2330-4243 (Print); ISSN: 2330-426X (Online) A Comparative
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationClinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant
The Clinical Significance of Anxiety Disorders and the DSM-5 Anxious Distress Specifier in Depressed Patients Clinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant Rhode Island
More informationTIAGABINE. THERAPEUTICS Brands Gabitril see index for additional brand names. Generic? Yes
TIAGABINE THERAPEUTICS Brands Gabitril see index for additional brand names Generic? Yes Class Anticonvulsant; selective GABA reuptake inhibitor (SGRI) Commonly Prescribed for (bold for FDA approved) Partial
More informationNortriptyline vs amitriptyline in elderly
Nortriptyline vs amitriptyline in elderly Amitriptyline (Elavil ) vs other antidepressants - comparative analysis amitriptyline vs divalproate, amitriptyline vs trazodone. Learn what other patients are
More informationDepression After Traumatic Brain Injury (TBI)
Depression After Traumatic Brain Injury (TBI) A resource for individuals with traumatic brain injury and their supporters This presentation is based on TBI Model Systems research and was developed with
More informationThe Emperor s New Drugs: Medication and Placebo in the Treatment of Depression
The Emperor s New Drugs: Medication and Placebo in the Treatment of Depression Irving Kirsch, PhD Associate Director, Program in Placebo Studies Harvard Medical School Professor Emeritus of Psychology
More informationFDA CLEARS NEUROSTAR TMS THERAPY FOR THE TREATMENT OF DEPRESSION
FOR IMMEDIATE RELEASE FDA CLEARS NEUROSTAR TMS THERAPY FOR THE TREATMENT OF DEPRESSION First and Only Non-systemic and Non-invasive Treatment Cleared for Patients Who Have Not Benefited From Prior Antidepressant
More informationRecognizing and Responding to Inadequately Treated Major Depressive Disorder (MDD)
Objectives Recognizing and Responding to Inadequately Treated Major Depressive Disorder (MDD) Discuss the burden of MDD on the individual and society Explore the negative impact of residual symptoms Identify
More informationTREATING MAJOR DEPRESSIVE DISORDER
TREATING MAJOR DEPRESSIVE DISORDER A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Second Edition, originally published in April 2000.
More informationDepression often comorbid with alcohol dependence 1.6x higher rate of alcohol dependence in depressed subjects Depressed subjects with alcohol
Lindsay French PGY3 Depression often comorbid with alcohol dependence 1.6x higher rate of alcohol dependence in depressed subjects Depressed subjects with alcohol dependence have complicated course of
More informationA Retrospective Claims Analysis of Medication Adherence and. Persistence Among Patients Taking Antidepressants
A Retrospective Claims Analysis of Medication Adherence and Persistence Among Patients Taking Antidepressants for the Treatment of Major Depressive Disorder (MDD) Katelyn R. Keyloun A thesis submitted
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 5. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationTreatment strategies in major depression What to use when?
Treatment strategies in major depression What to use when? Michael Bauer, MD, PhD Professor and Chair of Psychiatry University Hospital Carl Gustav Carus Technische Universität Dresden Germany First-line
More informationThe Louis de la Parte Florida Mental Health Institute
Data Brief December 2003 Mary Rose Murrin, M.A. Kelley Dhont, M.S. David Thornton, M.A. The Louis de la Parte Florida Mental Health Institute Children s Psychotropic Medication Use by Age and Diagnostic
More informationDepression & Anxiety in Adolescents
Depression & Anxiety in Adolescents Objectives 1) Review diagnosis of anxiety and depression in adolescents 2) Provide overview of evidence-based treatment options 3) Increase provider comfort level with
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 6. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationBipolar Disorder in Youth
Bipolar Disorder in Youth Janet Wozniak, M.D. Associate Professor of Psychiatry Director, Pediatric Bipolar Disorder Research Program Harvard Medical School Massachusetts General Hospital Pediatric-Onset
More informationDepression and Suicide: Tackling the Public Health Challenge
Depression and Suicide: Tackling the Public Health Challenge June 13, 2008 Kelly Posner, Ph.D. Columbia University New York State Psychiatric Institute 1 Scope of the Problem: Depression World Health Organization
More informationOptimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE
Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE Chan-Hyung Kim, MD Severance Mental Health Hospital Institute of Behavioral Science in Medicine Diagnostic Criteria Pyramid Etiologic Pathophysiologic
More informationGUIDELINES FOR THE USE OF PSYCHOACTIVE MEDICATIONS IN INDIVIDUALS WITH CO-OCCURRING SUBSTANCE USE DISORDERS
City and County of San Francisco Mayor Gavin Newsom Department of Public Health Community Behavioral Health Services 1380 Howard Street 5 th Floor San Francisco, CA 94103 GUIDELINES FOR THE USE OF PSYCHOACTIVE
More informationConsultant Pharmacist Approach to Major Depressive Disorder
Consultant Pharmacist Approach to Major Depressive Disorder ALAN OBRINGER RPH, CPH, CGP PRESIDENT/OWNER GUARDIAN PHARMACY OF ORLANDO Objectives What is Depression? Discuss the epidemiology of depression
More informationConsultant Pharmacist Approach to Major Depressive Disorder ALAN OBRINGER RPH, CPH, CGP PRESIDENT/OWNER GUARDIAN PHARMACY OF ORLANDO
Consultant Pharmacist Approach to Major Depressive Disorder ALAN OBRINGER RPH, CPH, CGP PRESIDENT/OWNER GUARDIAN PHARMACY OF ORLANDO Objectives What is Depression? Discuss the epidemiology of depression
More informationTreatment Options for Bipolar Disorder Contents
Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8
More informationIs Vilazodone Really the Answer to the Delay Associated with the Onset of Antidepressant Action of SSRIs? A Randomised Control Trial
International Journal of Clinical Psychiatry 2018, 6(1): 9-18 DOI: 10.5923/j.ijcp.20180601.02 Is Vilazodone Really the Answer to the Delay Associated with the Onset of Antidepressant Action of SSRIs? A
More informationChildren s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
More informationElavil (amitriptyline)
Generic name: Amitriptyline Available strengths: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg tablets; 10 mg/ml injection Available in generic: Yes Drug class: Tricyclic antidepressant General Information
More informationPharmacists in Medication Adherence in Psychiatric Patients
Pharmacists in Medication Adherence in Psychiatric Patients Mamta Parikh, PharmD, BCPS, BCPP Assistant Professor, Clinical and Administrative Sciences Notre Dame of Maryland University School of Pharmacy
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationDepression: selective serotonin reuptake inhibitors
Depression: selective serotonin reuptake inhibitors Selective serotonin reuptake inhibitors (SSRIs) are considered first-line treatment for the majority of patients with depression. citalopram and fluoxetine
More informationDouble-blind comparison of fluoxetine and nortriptyline in the treatment of moderate to severe major depression
Journal of Clinical Pharmacy and Therapeutics (2003) 28, 379 384 Double-blind comparison of fluoxetine and nortriptyline in the treatment of moderate to severe major depression S. Akhondzadeh* PhD, H.Faraji*
More informationWellbutrin/Wellbutrin-SR/ Wellbutrin-XL (bupropion)
Wellbutrin/Wellbutrin-SR/ Wellbutrin-XL (bupropion) Generic name: Bupropion Available strengths: 75 mg, 100 mg immediate-release tablets; 100 mg, 150 mg, 200 mg sustained-release tablets (Wellbutrin-SR);
More informationA Study of Suicidal Tendency among Annamalai University Students
The International Journal of Indian Psychology ISSN 2348-5396 (e) ISSN: 2349-3429 (p) Volume 3, Issue 3, No.1, DIP: 18.01.003/20160303 ISBN: 978-1-365-03416-9 http://www.ijip.in April - June, 2016 A Study
More informationClass Update: Second Generation Antidepressant Medications. Dossier received: Yes
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAntidepressant Medication Therapy in Primary Care July 25, 2013
New York State Collaborative Care Initiative Antidepressant Medication Therapy in Primary Care July 25, 2013 http://uwaims.org Presenter Building on 25 years of Research and Practice in Integrated Mental
More informationBenzodiazepine as an Adjuvant in Management of Depression
Original Article Benzodiazepine as an Adjuvant in Management of Depression Girish K and Moulya Nagraj* Department of Pharmacology, Kempe Gowda Institute of Medical Sciences, Bangalore - 560070, India ABSTRACT
More information